Current Status of Hormonal Therapy of Fibrocystic Breast Disease a

[1]  L. Dogliotti,et al.  Prolactin and thyrotropin response to thyrotropin-releasing hormone in premenopausal women with fibrocystic disease of the breast. , 1985, Hormone research.

[2]  L. Dogliotti,et al.  Thyroid hormone levels in human breast cyst fluid. , 1984, Acta endocrinologica.

[3]  M. Breckwoldt,et al.  Serum Prolactin Levels in Patients With Fibrocystic Breast Disease , 1984, Obstetrics and gynecology.

[4]  G. Muccioli,et al.  Presence and characterization of prolactin receptors in human benign breast tumours. , 1984, European journal of cancer & clinical oncology.

[5]  M. Dowsett,et al.  Endocrine effects of danazol in the treatment of endometriosis , 1984, British journal of obstetrics and gynaecology.

[6]  M. Dowsett,et al.  Prognostic significance of serum prolactin levels in advanced breast cancer. , 1983, British Journal of Cancer.

[7]  L. Dogliotti,et al.  Correlation between Levels of Dehydroepiandrosterone-Sulphate and Prolactin in Human Breast Cyst Fluid , 1982, Tumori.

[8]  F. Kuttenn,et al.  Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. , 1982, The Journal of clinical endocrinology and metabolism.

[9]  R. Mansel,et al.  CONTROLLED TRIAL OF THE ANTIGONADOTROPIN DANAZOL IN PAINFUL NODULAR BENIGN BREAST DISEASE , 1982, The Lancet.

[10]  T. G. Muldoon.  Interplay between estradiol and prolactin in the regulation of steroid hormone receptor levels, nature, and functionality in normal mouse mammary tissue. , 1981, Endocrinology.

[11]  K J Ryan,et al.  Danazol: endocrine pharmacology and therapeutic applications. , 1981, American journal of obstetrics and gynecology.

[12]  P. Fioretti,et al.  Inhibitory effect of the dopamine agonist bromocriptine on the postcastration gonadotrophin rise in women. , 1981, The Journal of clinical endocrinology and metabolism.

[13]  K. Menon,et al.  Estrogenic and antiestrogenic effects of danazol administration in studies of estradiol receptor binding. , 1981, American journal of obstetrics and gynecology.

[14]  A. Malcolm.  Production and processing of prolactin , 1981, Nature.

[15]  S. Duck,et al.  Danazol may cause female pseudohermaphroditism. , 1981, Fertility and sterility.

[16]  B. Sherman,et al.  Danazol: endocrine consequences in healthy women. , 1981, American journal of obstetrics and gynecology.

[17]  H. Zimmerman,et al.  DANAZOL AND LIVER DAMAGE , 1980, The Lancet.

[18]  G. Chamness,et al.  Danazol binding and translocation of steroid receptors. , 1980, American journal of obstetrics and gynecology.

[19]  K. Menon,et al.  Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotropin-receptor interaction and adenosine 3',5' cyclic monophosphate formation. , 1980, American journal of obstetrics and gynecology.

[20]  E. Rebhan,et al.  [Prolactin in serum and anamnestic data of women with cystic disease of the breast (author's transl)]. , 1980, Geburtshilfe und Frauenheilkunde.

[21]  L. Dogliotti,et al.  [Antiprolactin therapy in the treatment of benign lesions of the breast. Comparison of bromocryptine and methergoline]. , 1979, Minerva medica.

[22]  C. Laurell,et al.  A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. , 1979, The Journal of clinical endocrinology and metabolism.

[23]  B. Sherman,et al.  Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. , 1979, The Journal of clinical investigation.

[24]  I. Ricciardi,et al.  Tamoxifen-induced regression of benign breast lesions. , 1979, Obstetrics and gynecology.

[25]  G. Tolis,et al.  Prolactin and Deficient Luteal Function , 1979, Obstetrics and gynecology.

[26]  W. Dmowski,et al.  Endocrine properties and clinical application of danazol. , 1979, Fertility and sterility.

[27]  F. Halberg,et al.  Circadian mesor-hyperprolactinemia in fibrocystic mastopathy. , 1979, The American journal of medicine.

[28]  D. Graham,et al.  Adult pre-sacral teratoma. , 1979, Postgraduate medical journal.

[29]  J. Day.  Clinical trials in the premenstrual syndrome , 1979 .

[30]  L. Dogliotti,et al.  Treatment of benign breast disease with bromocriptine , 1979, Journal of endocrinological investigation.

[31]  F. Kuttenn,et al.  [The treatment of benign pathological conditions of the breasts with progesterone and progestogens. The results according to the type of breast condition (260 case records) (author's transl)]. , 1978, Journal de gynecologie, obstetrique et biologie de la reproduction.

[32]  W. Malarkey,et al.  Disordered nocturnal prolactin regulation in women with breast cancer. , 1977, Cancer research.

[33]  P. Franchimont,et al.  The effect of danazol on anterior pituitary function. , 1977, Fertility and sterility.

[34]  E. N. Cole,et al.  Serum prolactin concentrations in benign breast disease throughout the menstrual cycle. , 1977, European journal of cancer.

[35]  I. Mowszowicz,et al.  Inadequate corpus luteal function in women with benign breast diseases. , 1977, The Journal of clinical endocrinology and metabolism.

[36]  A. Hsueh,et al.  REGULATION OF ESTROGEN RECEPTOR REPLENISHMENT BY PROGESTERONE * , 1977, Annals of the New York Academy of Sciences.

[37]  V. Cararach,et al.  Treatment of Fibrocystic Disease of the Breast With a Prolactin Inhibitor: 2-Br-Alpha- Ergocryptine (CB-154) , 1976, Obstetrics and gynecology.

[38]  Lauersen Nh,et al.  The effect of danazol in the treatment of chronic cystic mastitis. , 1976 .

[39]  H. Rochefort,et al.  Regulation of estrogen receptors in ovarian-dependent rat mammary tumors. I. Effects of castration and prolactin. , 1976, Endocrinology.

[40]  T. Ranta,et al.  HYPERPROLACTINÆMIA AND LUTEAL INSUFFICIENCY , 1976, The Lancet.

[41]  A. Mcneilly,et al.  A possible role for prolactin in control of steroid secretion by the human Graafian follicle , 1974, Nature.

[42]  R. Greenblatt,et al.  Clinical studies with an antigonadotropin-Danazol. , 1971, Fertility and sterility.